FDA Approves First-Ever Drug for Friedreich's Ataxia After 30-Year Wait

The U.S. Food and Drug Administration has approved Skyclarys (omaveloxolone), the first treatment for Friedreich's ataxia, a rare inherited neurodegenerative disorder that typically emerges in childhood and progressively impairs coordination, muscle strength, and heart function. Developed by Reata Pharmaceuticals, the drug gained approval after a Phase 2 trial showed improved neurological function in patients, marking a historic shift from symptom management to disease modification. Friedreich's ataxia affects roughly 5,000 people in the U.S. and 15,000 worldwide, with most patients relying on wheelchairs within 10 to 20 years of diagnosis. The approval follows decades of research and advocacy by organizations like the Friedreich's Ataxia Research Alliance, which helped fund early development. Skyclarys works by activating the Nrf2 pathway, reducing oxidative stress and improving mitochondrial function, addressing the underlying pathology. The FDA's decision, announced in February 2023, was based on data from the MOXIe trial and a post-hoc analysis, with common side effects including headache, nausea, and abdominal pain. This milestone could accelerate research into other rare neurological conditions and offers hope for patients who have long awaited a targeted therapy.